Sponsor Pipeline

Tanabe Pharma America, Inc. Clinical Trial Pipeline

Data updated daily from ClinicalTrials.gov — last refresh 2026-08-16
2
Active Trials
2
Recruiting
1
Phase 3
10
Disease Areas
1
Changes, 30 Days
What Changed in the Last 30 Days
DetectedTrialChange
2026-08-12 NCT05005975
Extension Study to Evaluate Safety and Tolerability of Oral Dersimelagon (MT-7117) in…		 Trial sites reduced: 51 -> 45 locations
Active Trials by Phase
Phase 3
1
Phase 1/2
1
Active Trials
NCT IDTitleConditionStatus
Phase 3
NCT05005975 Extension Study to Evaluate Safety and Tolerability of Oral Dersimelagon (MT-7117) in… EPP Recruiting
Phase 1/2
NCT06943521 A Study of MT-4561 in Patients With Various Advanced Solid Tumors Head and Neck Squamous Cell Carcinoma (HNSCC) Recruiting
Disease Areas
Non-Small Cell Lung Cancer (NSCLC) (1) Lung Cancer (1) Breast Cancer (1) Prostate Cancer (1) Pancreatic Cancer (1) Gastric Cancer (1) Bladder Cancer (1) Ovarian Cancer (1) Cervical Cancer (1) Endometrial Cancer (1)
Get alerts when Tanabe Pharma America, Inc.'s trials change
Status changes, date slips, and new filings — detected daily, delivered to your inbox.
Start monitoring free